Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis : Phase 2 Trial For Iptacopan Shows Positive Results in Kidney Disease C3 Glomerulopathy Patients

06/07/2021 | 11:21pm EDT


© MT Newswires 2021
All news about NOVARTIS AG
07/29Rubius Therapeutics Taps Dannielle Appelhans as Chief Operating Officer
DJ
07/28XOMA : Secures FDA's Orphan Drug Designation for Investigational Pancreatic Canc..
MT
07/28GLOBAL MARKETS LIVE : Apple, Alphabet, Facebook, Pfizer, McDonald's...
07/28XOMA Gets Orphan Drug Designation for Pancreatic Cancer Treatment
DJ
07/28NOVARTIS AG : Sell rating from JP Morgan
MD
07/27NOVARTIS : Gets US FDA's Orphan Drug Designation For Pancreatic Cancer Treatment
MT
07/27NOVARTIS : Morgan Stanley Lowers Price Target on Novartis, Maintains Overweight/..
MT
07/27NOVARTIS AG : Gets a Buy rating from Morgan Stanley
MD
07/27Artios raises USD153m in Series C financing
DJ
07/23NOVARTIS AG : Buy rating from UBS
MD
More news
Financials (USD)
Sales 2021 51 962 M - -
Net income 2021 9 849 M - -
Net Debt 2021 22 988 M - -
P/E ratio 2021 20,5x
Yield 2021 3,53%
Capitalization 226 B 225 B -
EV / Sales 2021 4,78x
EV / Sales 2022 4,47x
Nbr of Employees 109 000
Free-Float 87,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 92,64 $
Average target price 105,52 $
Spread / Average Target 13,9%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG0.28%225 343
JOHNSON & JOHNSON9.42%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.16.30%239 637
ELI LILLY AND COMPANY44.22%221 348
NOVO NORDISK A/S35.94%212 048